How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,243 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)

Measures Go to Primary Outcome Measures : Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the target population [ Time Frame: 15 days ] Secondary Outcome Measures : Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the first cycle of chemotherapy in the additional population [ Time Frame: 15 days ] Proportion of patients experiencing a maximum Grade ≥ 2 diarrhea during the second and third cycle of chemotherapy - target (...) of first, second and third cycle of chemotherapy ] Proportion of patients: who required i.v. fluids due to CID, who required changes to the primary therapy due to CID, who used rescue medication (i.e. medication used for treatment of diarrhea) by cycle (Cycle 1, 2 and 3) - target population [ Time Frame: 15 days of first, second and third cycle of chemotherapy ] Proportion of patients having a maximum Grade ≥ 2 diarrhea - shift from Cycle 1 to Cycle 2 and from Cycle 2 to Cycle 3 - target population

2015 Clinical Trials

82. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine.

to the individual prevention of the traveler's Malaria, diarrhea and sexually transmitted infections. [ Time Frame: At day 1 ] Evaluated by a post-consultation memorization survey Secondary Outcome Measures : Quality score of the support consultation evaluating the memorization of Information by travelers. [ Time Frame: At day 1 ] Evaluated by memorisation survey Level of satisfaction of travelers [ Time Frame: At day 1 ] The level of satisfaction will be assessed by a visual scale. The relevance of the choice (...) Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

83. Evaluating an Intervention to Increase Use of Call Centre Support for Self-managed Medical Abortion

doses Self-reported satisfaction with self-administration of MA [ Time Frame: Day 14 after taking the first pill ] Satisfaction with the overall process, would recommend to a friend who needed an abortion, would use the same method again if needed an abortion again, feeling adequately prepared for various aspects of the medical abortion process. Secondary Outcome Measures : Cost of intervention per unit of call centre use [ Time Frame: Day 14 after taking first pill ] Increased unit cost (...) needing IV antibiotics and undiagnosed (at the time of MA administration) ectopic pregnancy needing surgery or other treatment, a continuing pregnancy needing an uterine aspiration, an incomplete abortion needing uterine aspiration or further medication, severe allergic reaction, severe vomiting or diarrhea and admission to a health facility for any of the above. Other Outcome Measures: Proportion of pharmacy workers encouraging mystery clients to use the MSZ call centre number [ Time Frame: Within 4

2017 Clinical Trials

84. Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay

Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay (TM-B1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03343691 Recruitment Status : Recruiting First

2017 Clinical Trials

85. Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study) Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study) - Full Text View - ClinicalTrials.gov Hide glossary Glossary (...) Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study

2017 Clinical Trials

86. Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients (PubMed)

with additional TCM (intervention, n = 156) groups. The primary endpoint was QOL scores; secondary endpoints were the toxicity and safety of the regimens. The NP/NC regimen caused mild (grade 1 or 2) non-hematologic toxic effects in the patients comprising vomiting (43.6%), fatigue (36.9%), pain (23%), dry mouth (27.6%) and diarrhea (7.9%). The incidence of adverse events was significantly lower in the intervention group than in the control group (0.57% vs 4.02%, P = 0.037). Transient severe (grade 3 or 4 (...) Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients The aim was to evaluate the effects of traditional Chinese medicine (TCM) as a combination medication with adjuvant chemotherapy on postoperative early stage non-small cell lung cancer (NSCLC) patients. The 314 patients with completely resected stage IB, II or IIIA cancers were assigned into vinorelbine plus cisplatin/carboplatin (NP/NC) (control, n = 158) and NP/NC

Full Text available with Trip Pro

2017 Scientific reports

87. Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route

preparation. Intervention - Lyophilized Microbiota will be delivered orally Biological: Lyophilized Microbiota Lyophilized Microbiota will be delivered orally. Outcome Measures Go to Primary Outcome Measures : Safety as Assessed by Number of Participants With Any Adverse Events (AE)s [ Time Frame: 6 months after the procedure ] any untoward medical occurrence associated with the use of PRIM-DJ2727 whether or not considered drug related is considered as an adverse event (AE) Secondary Outcome Measures (...) Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2014 Clinical Trials

88. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-3) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02107196 Recruitment Status : Completed First Posted : April 8, 2014

2014 Clinical Trials

89. Lactose-free Milk in Infants With Acute Diarrhea in a Developing Country

Last Update Posted : February 15, 2019 Sponsor: American University of Beirut Medical Center Information provided by (Responsible Party): Mona Nabulsi, American University of Beirut Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether lactose-free milk will shorten the diarrhea duration and decrease its severity in formula-fed infants presenting to the Emergency Department (ED) or pediatric clinics with acute diarrhea. Condition (...) milk No Intervention: Regular infant milk Regular infant milk formula and anti-diarrheic diet for 7 days. Outcome Measures Go to Primary Outcome Measures : Diarrhea Duration [ Time Frame: From onset of illness till the day of last diarrheic stool passed. ] number of days with 3 or more loose or watery stools Secondary Outcome Measures : Weight Loss [ Time Frame: 7 days ] Percent weight loss from baseline Illness Visits [ Time Frame: 7 days ] Number of participants with illness visits

2014 Clinical Trials

90. Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients

at high risk for this infection. Condition or disease Intervention/treatment Phase Clostridium Difficile Diarrhea Drug: Metronidazole Drug: Placebo Phase 4 Detailed Description: Clostridium Difficile infection or C. Diff (CDI) is an infection that causes severe diarrhea. Risk factors for this infection include hospitalization, the use of antibiotics, along with medications that decrease the acid in the stomach. This infection leads to a disease which is difficult to treat and can cause serious (...) Drug: Placebo Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days Other Name: corn starch pill Outcome Measures Go to Primary Outcome Measures : The Incidence of Clostridium Difficile Diarrhea in Both Study Groups at 30 Days Post Broad Spectrum Antibiotic Use. [ Time Frame: 30 days ] Secondary Outcome Measures : Determine Differences in Clostridium Difficile Diarrhea Incidence Between Patients on Piperacillin/Tazobactam vs. Patients on Ciprofloxacin. [ Time Frame: 30 days

2014 Clinical Trials

91. A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

from birth to < 2 years) or number of UBMs (for ages ≥ 2 years to < 18 years). Secondary Outcome Measures : Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days [ Time Frame: Up to day 19 ] SCR at EOT + 9 days was defined as CCR (EOT + 2 days) without CDAD recurrence until assessment at EOT +9 days during the follow-up period. Recurrence for ages from birth to < 2 years was defined as re-establishment of watery diarrhea after CCR to an extent that was greater than (...) A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers

2014 Clinical Trials

92. 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings

mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days) Other Name: Bovine colostrum Sham Comparator: No 64N Nutraceutical Culturally appropriate 12 ounce warm drink daily for 1 week (7 days). Other: No 64N Nutraceutical 12 ounce warm drink daily for 1 week (7 days) Outcome Measures Go to Primary Outcome Measures : Mortality from childhood diarrhea and pneumonia [ Time Frame: Assessed every 3 months for 4.5 years ] Secondary Outcome Measures : Medical visits for childhood (...) 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2014 Clinical Trials

93. Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea

Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02318992 Recruitment Status : Unknown Verified November 2016

2014 Clinical Trials

94. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.

. Outcome Measures Go to Primary Outcome Measures : Efficacy measured by the decrease in the intensity of diarrhea and / or anti-diarrheal consumption [ Time Frame: 1 month ] Effectiveness of acetylsalicylic acid versus diosmectite Secondary Outcome Measures : Toxicity [ Time Frame: Three months ] Diarrhea decrease 3 months after the introduction of acetylsalicylic acid or diosmectite; Proportion of patients with a decrease in the grade of diarrhea during the months following the introduction (...) Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

95. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-05) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02320318 Recruitment Status : Withdrawn First Posted : December 19, 2014

2014 Clinical Trials

96. Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

, 2018 Sponsor: Montefiore Medical Center Information provided by (Responsible Party): Olga Aroniadis, Montefiore Medical Center Study Details Study Description Go to Brief Summary: The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome (IBS-D); (2) determine the impact of FMT on the intestinal microbiome of patients with IBS-D (...) Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2014 Clinical Trials

97. Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

: February 2019 Keywords provided by Jeffrey Hyams, MD, Connecticut Children's Medical Center: IBS IBS-D SBI Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Diarrhea Irritable Bowel Syndrome Disease Pathologic Processes Signs and Symptoms, Digestive Signs and Symptoms Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Immunoglobulins Antibodies Immunologic Factors Physiological Effects of Drugs (...) Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2014 Clinical Trials

98. Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea (CJCV1-01) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02067676 Recruitment Status : Completed First Posted : February 20, 2014 Results First Posted : January 25, 2018 Last Update Posted : February 23

2014 Clinical Trials

99. Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Comparator: Placebo Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h. Other: Placebo Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate Outcome Measures Go to Primary Outcome Measures : use of antimicrobial medications [ Time Frame: within 5 days of enrollment ] Secondary Outcome Measures : Patient's perceived need for antibiotics [ Time Frame: Within 48 h of enrollment ] additional care obtained for diarrhea [ Time Frame (...) : within 48 h of enrollment ] Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness Additional care obtained for diarrheal illness [ Time Frame: within 5 days of enrollment ] Use of antidiarrheal medications, visits to other health professionals for diarrhea or complications of diarrhea, or expenditures on consultations and treatments for diarrheal illness Disease severity

2014 Clinical Trials

100. A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Frame: Up to 38 days ] Global cure rate is the rate of the subjects satisfying both of the following: being cured at the completion of study drug administration; without recurrence during the follow-up period Secondary Outcome Measures : Cure rate [ Time Frame: Day 10 -11 of the study period ] Recurrence rate of CDAD [ Time Frame: during the 4-week follow-up period, up to Day 38 ] Time to resolution of diarrhea [ Time Frame: up to 38 days ] Microbiological efficacy [ Time Frame: Up to 38 days (...) A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>